Reporter

Eric Nestler, MD, PhD, renowned for his studies of the molecular basis of drug addiction and depression, discusses his latest research findings during last week’s Discovery Lecture.
April 28, 2022

Nestler’s Discovery Lecture

Eric Nestler, MD, PhD, renowned for his studies of the molecular basis of drug addiction and depression, discusses his latest research findings during last week’s Discovery Lecture.

Patient care technician Pamela Spencer holds up a handwritten letter from a patient’s parent filled with praise for Spencer’s special bond with her patients.
April 27, 2022

Patients and families share positive feedback on their experiences at VUMC

To mark Patient Experience Week, a national event to celebrate how health care providers impact patient experience, several employees from across the Medical Center were invited to participate in a video to share their thoughts about why patient experience is so important.

April 26, 2022

New Clinician Spotlight: Aaron McMurtray

Specializing in dementia and Alzheimer’s disease, neurologist Aaron McMurtray, MD, PhD, recently joined Vanderbilt University Medical Center as associate professor of Neurology.

April 26, 2022

Monroe Carell Jr. Children’s Hospital at Vanderbilt/CDC investigate mysterious liver disease in children

Physicians at Monroe Carell Jr. Children’s Hospital at Vanderbilt are collaborating with the CDC and other hepatologists around the country to help figure out the origins of a mysterious liver disease affecting children ages 1 month to 16 years old.

April 26, 2022

Calculating risk for uterine fibroids

Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies.

April 25, 2022

Molecular testing across tumor types

The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.